In order to therapeutically block glycolytic flux in cancer cells, we selected GAPDH as a target on the basis of our previous works, in which we tested a set of 3-bromo-isoxazoline derivatives (Figure 1b) that were designed and synthetized as inhibitors of PfGAPDH [12,14]. Here, GAPDH is linked to cancer.